Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.
4Q Earnings: $410 million (loss of $3.4 billion 4Q24) ...
1h
Hosted on MSNPfizer earnings exceed estimatesPfizer reported better-than-expected quarterly profits on Tuesday behind cost cuts and growth in some non-Covid-related products including the blood clot drug Eliquis. Other pharmaceuticals with ...
Since the beginning of 2024, PFE stock has underperformed the S&P 500 index, delivering -3% returns compared to the index’s ...
Discover the advantages of needle-free vaccines and which companies are developing their own promising delivery solutions in ...
The United States is seeing a second peak in flu cases this season. After doctor’s office visits for flu dipped early this ...
A Georgia sculptor gave birth during the coronavirus pandemic. Five years later, she is designing a monument honoring those who have died with COVID-19.
Pfizer CEO Albert Bourla said there are "opportunities that probably outweigh the risks" of the Trump administration's ...
Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...
Pharma giant Merck on Tuesday announced in its earnings report that it would halt all shipments of HPV drug Gardasil to China ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results